Used as a metabolic byproduct of the neuromuscular blocking agent atracurium, DL-Laudanosine is primarily monitored in clinical settings due to its potential central nervous system effects. It crosses the blood-brain barrier and has been associated with excitatory activity, including seizures at high concentrations, particularly in patients with impaired renal function. Its accumulation during prolonged atracurium infusion necessitates careful patient monitoring in intensive care. Additionally, DL-Laudanosine serves as a chemical intermediate in the synthesis of certain alkaloids and pharmaceutical compounds, supporting research in neuropharmacology and drug development. It is also utilized in biochemical research for studying CNS effects and as a standard in analytical methods for biological samples.